A Phase I, Study to Evaluate the Safety and Tolerability of Intravenous EZN-2208 in Patients With Advanced Solid Tumors or Lymphoma (EZN-2208-02)
NCT00520390
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
34
Enrollment
INDUSTRY
Sponsor class
Conditions
Lymphoma
Advanced Solid Tumors
Interventions
DRUG:
EZN-2208
Sponsor
Enzon Pharmaceuticals, Inc.